Egg    (DrugBank: Egg)

2 diseases
IDDisease name (Link within this page)Number of trials
96Crohn disease6
310Congenital anomalies syndrome1

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03079700
(ClinicalTrials.gov)
August 1, 20129/3/2017Immune Modulation From Trichuris SuisMucosal and Systemic Immune Modulation From Trichuris Suis in a Self-infected IndividualCrohn Disease;Ulcerative Colitis;Intestinal HelminthiasisBiological: Trichuris suis eggsUniversity of AarhusNULLCompleted18 Years70 YearsMale1N/ANULL
2NCT02399683
(ClinicalTrials.gov)
February 201212/3/2015Immune Modulation From Trichuris TrichiuraMucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected IndividualCrohn Disease;Colitis, Ulcerative;Intestinal HelminthiasisBiological: Trichuris trichiura eggsUniversity of AarhusNULLCompleted18 Years70 YearsMale1N/ANULL
3EUCTR2006-000720-13-DE
(EUCTR)
27/10/201029/01/2010Study to evaluate the effectiveness and safety of 3 doses of embryonated eggs of the porcine whipworm compared to placebo (dummy drug) in the treatment of active Crohn's disease.Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease - TSO vs. placebo in active Crohn’s disease Induction of remission in active Crohn´s disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 250
Other descriptive name: Suspension containing 250 embryonated, viable TSO/15ml
Product Name: Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 2500
Other descriptive name: Suspension containing 2500 embryonated, viable TSO/15ml
Product Name: Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 7500
Other descriptive name: Suspension of 7500 embryonated, viable TSO/15ml
Dr. Falk Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
400Phase 2Czech Republic;Denmark;Austria;Germany;Switzerland
4EUCTR2006-000720-13-CZ
(EUCTR)
18/10/201030/06/2010Study to evaluate the effectiveness and safety of 3 doses ofembryonated eggs of the porcine whipworm compared to placebo(dummy drug) in the treatment of active Crohn's disease.Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease - TSO vs. placebo in active Crohn’s disease Induction of remission in active Crohn´s disease
MedDRA version: 16.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 250
Other descriptive name: Suspension containing 250 embryonated, viable TSO/15ml
Product Name: Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 2500
Other descriptive name: Suspension containing 2500 embryonated, viable TSO/15ml
Product Name: Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 7500
Other descriptive name: Suspension of 7500 embryonated, viable TSO/15ml
Dr. Falk Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
400Phase 2Czech Republic;Denmark;Austria;Germany;Switzerland
5EUCTR2006-000720-13-DK
(EUCTR)
22/06/201017/03/2010Study to evaluate the effectiveness and safety of 3 doses ofembryonated eggs of the porcine whipworm compared to placebo(dummy drug) in the treatment of active Crohn's disease.Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease - TSO vs. placebo in active Crohn’s disease Induction of remission in active Crohn´s disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 250
Other descriptive name: Suspension containing 250 embryonated, viable TSO/15ml
Product Name: Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 2500
Other descriptive name: Suspension containing 2500 embryonated, viable TSO/15ml
Product Name: Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 7500
Other descriptive name: Suspension of 7500 embryonated, viable TSO/15ml
Dr. Falk Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
400Phase 2Czech Republic;Austria;Denmark;Germany;Switzerland
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-000720-13-AT
(EUCTR)
07/04/201003/03/2010Study to evaluate the effectiveness and safety of 3 doses ofembryonated eggs of the porcine whipworm compared to placebo(dummy drug) in the treatment of active Crohn's disease.Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease - TSO vs. placebo in active Crohn’s disease Induction of remission in active Crohn´s disease
MedDRA version: 14.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 250
Other descriptive name: Suspension containing 250 embryonated, viable TSO/15ml
Product Name: Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 2500
Other descriptive name: Suspension containing 2500 embryonated, viable TSO/15ml
Product Name: Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml
Product Code: TSO 7500
Other descriptive name: Suspension of 7500 embryonated, viable TSO/15ml
Dr. Falk Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
400Phase 2Czech Republic;Denmark;Austria;Germany;Switzerland

310. Congenital anomalies syndrome    [ 10 clinical trials,   18 drugs,   (DrugBank: 10 drugs),   3 drug target genes,   7 drug target pathways]
Searched query = "Congenital anomalies syndrome", "Trisomy 1q", "9q34 deletion syndrome", "Cornelia de Lange syndrome", "CdLS", "Smith-Lemli-Opitz syndrome", "SLO syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 10 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00114634
(ClinicalTrials.gov)
June 200515/6/2005Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz SyndromeShort-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz SyndromeSmith-Lemli-Opitz SyndromeDietary Supplement: Egg yolk preparation with cholesterol;Dietary Supplement: Egg substitute, without cholesterolEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompleted4 Years17 YearsAll13Phase 2United States